BTIG initiated research coverage with a buy rating, calling the biotech’s experimental hair loss treatment a possible ‘GLP-1 moment.’
Communicating your story to the Street
BTIG initiated research coverage with a buy rating, calling the biotech’s experimental hair loss treatment a possible ‘GLP-1 moment.’